- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus settles class action suit
Sonus Pharmaceuticals has settled a class action suit brought against it in a California Superior Court. The litigation, filed in San Diego, claimed that the company did not communicate clearly about the status of the Food and Drug Administration’s
Sonus Pharmaceuticals has settled a class action suit brought against it in a California Superior Court. The litigation, filed in San Diego, claimed that the company did not communicate clearly about the status of the Food and Drug Administrations clearance of EchoGen, the companys ultrasound contrast agent. Although Bothell, WA-based Sonus believes that the complaint was without merit, it chose to settle rather than engage in the litigation. Terms of the settlement were not disclosed, although Sonus did state that the terms were not monetary.
On the EchoGen front, at the end of September Sonus filed a complete response to conditions outlined in the FDAs approvable letter, which the company received in April (SCAN 4/28/99). Sonus believes that it has provided sufficient answer to the agencys letter, and continues to wait for its response, according to Greg Sessler, CFO.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
